To date, there are no large-scale, randomised controlled trials (RCTs) the gold standard of clinical evidence that have conclusively demonstrated its efficacy for hair regrowth in humans
Many insurers still exclude weight management drugs, though this is slowly changing
6.6% of patients discontinue tirzepatide due to adverse effects during its phase 3 trial [47]
In a case series of 49 patients, the mean age was 51.2 years and the most common sites involved were the trunk, the head and neck, the extremities, and the acral areas [23]
This is underscored by concurrent improvements in -cell function, insulin sensitivity, and -cell function [74, 75]